Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Bottaro Website

Donald P. Bottaro, Ph.D.

Selected Publications

1)  Miki T, Fleming TP, Bottaro DP, Rubin JS, Ron D, Aaronson SA.
Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop.
Science. 251: 72-5, 1991.
2)  Rubin JS, Chan AM, Bottaro DP, Burgess WH, Taylor WG, Cech AC, Hirschfield DW, Wong J, Miki T, Finch PW.
A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.
Proc. Natl. Acad. Sci. U.S.A. 88: 415-9, 1991.
3)  Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA.
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
Science. 251: 802-4, 1991.
4)  Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH.
Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
Science. 267: 381-3, 1995.
5)  Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP.
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling.
Cancer Cell. 22: 250-62, 2012.
6)  Catenacci DV, Liao WL, Thyparambil S, Henderson L, Xu P, Zhao L, Rambo B, Hart J, Xiao SY, Bengali K, Uzzell J, Darfler M, Krizman DB, Cecchi F, Bottaro DP, Karrison T, Veenstra TD, Hembrough T, Burrows J.
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue.
PLoS ONE. 9: e100586, 2014.
7)  Zhang M, Luo Z, Liu H, Croce CM, Burke TR, Bottaro DP.
Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist.
Leukemia. 28: 948-51, 2014.
8)  Lee YH, Morrison BL, Bottaro DP.
Synergistic Signaling of Tumor Cell Invasiveness by Hepatocyte Growth Factor and Hypoxia.
J. Biol. Chem. [Epub ahead of print], 2014.
9)  Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
J. Clin. Oncol. 31: 181-6, 2013.
10)  Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS ONE. 8: e54014, 2013.
11)  Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N.
Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
PLoS ONE. 7: e42717, 2012.
12)  Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.
Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab.
J. Nucl. Med. 53: 1592-600, 2012.
13)  McKee TC, Rabe D, Bokesch HR, Grkovic T, Whitson EL, Diyabalanage T, Van Wyk AW, Marcum SR, Gardella RS, Gustafson KR, Linehan WM, McMahon JB, Bottaro DP.
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.
J. Nat. Prod. 75: 1632-6, 2012.
14)  Cecchi F, Bottaro DP.
Novel antagonists of heparin binding growth factors.
Oncotarget. 3: 911-2, 2012.
15)  Cecchi F, Rabe DC, Bottaro DP.
Targeting the HGF/Met signaling pathway in cancer therapy.
Expert Opin. Ther. Targets. 16: 553-72, 2012.
16)  Bokesch HR, Gardella RS, Rabe DC, Bottaro DP, Linehan WM, McMahon JB, McKee TC.
A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.
Chem. Pharm. Bull. 59: 1178-9, 2011.
17)  Liu F, Giubellino A, Simister PC, Qian W, Giano MC, Feller SM, Bottaro DP, Burke TR.
Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides.
Biopolymers. 2011.
18)  Grkovic T, Whitson EL, Rabe DC, Gardella RS, Bottaro DP, Linehan WM, McMahon JB, Gustafson KR, McKee TC.
Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression.
Bioorg. Med. Chem. Lett. 21: 2113-5, 2011.
19)  Mungunsukh O, Lee YH, Marquez AP, Cecchi F, Bottaro DP, Day RM.
A tandem repeat of a fragment of Listeria monocytogenes internalin B protein induces cell survival and proliferation.
Am. J. Physiol. Lung Cell Mol. Physiol. 299: L905-14, 2010.
20)  Felici A, Giubellino A, Bottaro DP.
Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.
J Cell Biochem. 111: 310-21, 2010.
21)  Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R.
Molecular diagnosis and therapy of kidney cancer.
Annu. Rev. Med. 61: 329-43, 2010.
22)  Cecchi F, Rabe DC, Bottaro DP.
Targeting the HGF/Met signalling pathway in cancer.
Eur. J. Cancer. 46: 1260-70, 2010.
23)  Peach ML, Tan N, Choyke SJ, Giubellino A, Athauda G, Burke TR, Nicklaus MC, Bottaro DP.
Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening.
J. Med. Chem. 52: 943-51, 2009.
24)  Linehan WM, Pinto PA, Bratslavsky G, Pfaffenroth E, Merino M, Vocke CD, Toro JR, Bottaro D, Neckers L, Schmidt LS, Srinivasan R.
Hereditary kidney cancer: unique opportunity for disease-based therapy.
Cancer. 115: 2252-61, 2009.
25)  Choi WJ, Kim SE, Stephen AG, Weidlich I, Giubellino A, Liu F, Worthy KM, Bindu L, Fivash MJ, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR.
Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids.
J. Med. Chem. 52: 1612-8, 2009.
26)  Linehan WM, Rubin JS, Bottaro DP.
Signaling Networks in Focus: VHL Loss of Function and Its Impact on Oncogenic Signaling Networks in Clear Cell Renal Cell Carcinoma.
Int J Biochem Cell Biol. 41: 753-756, 2009.
27)  Giubellino A, Linehan WM, Bottaro DP.
Targeting the Met signaling pathway in renal cancer.
Expert Rev Anticancer Ther. 9: 785-93, 2009.
28)  Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K.
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Clin. Cancer Res. 15: 4292-8, 2009.
29)  Linehan WM, Rubin JS, Bottaro DP.
VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma.
Int. J. Biochem. Cell Biol. 41: 753-6, 2009.
30)  Bottaro DP, Tan N, Linehan WM.
Figg W, Folkman J, eds.
Regulation of Angiogenesis by von Hippel Lindau Protein and Hypoxia Inducible Factor 2. In: Angiogenesis: An Integrative Approach from Science to Medicine.
Boston: Springer; 2008. p. 181-191 [Book Chapter]
31)  Giubellino A, Burke TR, Bottaro DP.
Grb2 signaling in cell motility and cancer.
Expert Opin. Ther. Targets. 12: 1021-33, 2008.
32)  Giubellino A, Shi ZD, Jenkins LM, Worthy KM, Bindu LK, Athauda G, Peruzzi B, Fisher RJ, Appella E, Burke TR, Bottaro DP.
Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist.
J. Med. Chem. 51: 7459-68, 2008.
33)  Lee SJ, Lattouf JB, Xanthopoulos J, Linehan WM, Bottaro DP, Vasselli JR.
Von Hippel-Lindau Tumor Suppressor Gene Loss in Renal Cell Carcinoma Promotes Oncogenic Epidermal Growth Factor Receptor Signaling via Akt-1 and MEK1.
Eur. Urol. 2008.
34)  Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L.
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.
Clin. Cancer Res. 13: 671s-679s, 2007.
35)  Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, Medepalli S, Trepel JB, Burke TR, Bottaro DP.
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist.
Cancer Res. 67: 6012-6, 2007.
36)  Rubin JS, Bottaro DP.
Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function.
Clin. Cancer Res. 13: 4660-3, 2007.
37)  Liu F, Worthy KM, Bindu L, Giubellino A, Bottaro DP, Fisher RJ, Burke TR.
Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis.
Org. Biomol. Chem. 5: 367-72, 2007.
38)  Peruzzi B, Bottaro DP.
Beta-catenin signaling: linking renal cell carcinoma and polycystic kidney disease.
Cell Cycle. 5: 2839-41, 2006.
39)  Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP.
c-Met ectodomain shedding rate correlates with malignant potential.
Clin. Cancer Res. 12: 4154-62, 2006.
40)  Dharmawardana PG, Peruzzi B, Giubellino A, Burke TR, Bottaro DP.
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy.
Anticancer Drugs. 17: 13-20, 2006.
41)  Peruzzi B, Bottaro DP.
Targeting the c-Met signaling pathway in cancer.
Clin. Cancer Res. 12: 3657-60, 2006.
42)  Peruzzi B, Athauda G, Bottaro DP.
The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
Proc. Natl. Acad. Sci. U.S.A. 103: 14531-6, 2006.
43)  Kang SU, Shi ZD, Worthy KM, Bindu LK, Dharmawardana PG, Choyke SJ, Bottaro DP, Fisher RJ, Burke TR.
Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform.
J. Med. Chem. 48: 3945-8, 2005.
44)  Bottaro DP, Linehan WM.
Multifocal renal cancer: genetic basis and its medical relevance.
Clin. Cancer Res. 11: 7206-8, 2005.
45)  Shi ZD, Karki RG, Oishi S, Worthy KM, Bindu LK, Dharmawardana PG, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR.
Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic.
Bioorg. Med. Chem. Lett. 15: 1385-8, 2005.
46)  Ruggiero M, Bottaro DP, Liguri G, Gulisano M, Peruzzi B, Pacini S.
0.2 T magnetic field inhibits angiogenesis in chick embryo chorioallantoic membrane.
Bioelectromagnetics. 25: 390-6, 2004.
47)  Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L.
Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Clin. Cancer Res. 10: 6282S-9S, 2004.
48)  Dharmawardana PG, Giubellino A, Bottaro DP.
Hereditary papillary renal carcinoma type I.
Curr. Mol. Med. 4: 855-68, 2004.
49)  Soriano JV, Liu N, Gao Y, Yao ZJ, Ishibashi T, Underhill C, Burke TR, Bottaro DP.
Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists.
Mol. Cancer Ther. 3: 1289-99, 2004.
50)  Bottaro DP, Liotta LA.
Cancer: Out of air is not out of action.
Nature. 423: 593-5, 2003.
51)  Ishimoto S, Ishibashi T, Bottaro DP, Kaga K.
Direct application of keratinocyte growth factor, basic fibroblast growth factor and transforming growth factor-alpha during healing of tympanic membrane perforation in glucocorticoid-treated rats.
Acta Otolaryngol. 122: 468-73, 2002.
52)  Liu F, Schaphorst KL, Verin AD, Jacobs K, Birukova A, Day RM, Bogatcheva N, Bottaro DP, Garcia JG.
Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta.
FASEB J. 16: 950-62, 2002.
53)  Day RM, Soon L, Breckenridge D, Bridges B, Patel BK, Wang LM, Corey SJ, Bottaro DP.
Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways.
Oncogene. 21: 2201-11, 2002.
54)  Bottaro DP, Liebmann-Vinson A, Heidaran MA.
Molecular signaling in bioengineered tissue microenvironments.
Ann. N. Y. Acad. Sci. 961: 143-53, 2002.
55)  Damsky C, Heidaran M, Bottaro D, Crossin K, Ducy P, Ingber D.
Molecular signaling: breakout session summary.
Ann. N. Y. Acad. Sci. 961: 164-7, 2002.
56)  Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW, Henkart PA, Bottaro DP, Soon L, Bonvini P, Lee SJ, Karp JE, Oh HJ, Rubin JS, Trepel JB.
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin.
Blood. 100: 982-90, 2002.
57)  Bottaro DP.
The role of extracellular matrix heparan sulfate glycosaminoglycan in the activation of growth factor signaling pathways.
Ann. N. Y. Acad. Sci. 961: 158, 2002.
58)  Rubin JS, Day RM, Breckenridge D, Atabey N, Taylor WG, Stahl SJ, Wingfield PT, Kaufman JD, Schwall R, Bottaro DP.
Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling.
J. Biol. Chem. 276: 32977-83, 2001.
59)  Reboul P, Pelletier JP, Tardif G, Benderdour M, Ranger P, Bottaro DP, Martel-Pelletier J.
Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade.
Arthritis Rheum. 44: 73-84, 2001.
60)  Atabey N, Gao Y, Yao ZJ, Breckenridge D, Soon L, Soriano JV, Burke TR, Bottaro DP.
Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions.
J. Biol. Chem. 276: 14308-14, 2001.
61)  Nekhai S, Bottaro DP, Woldehawariat G, Spellerberg A, Petryshyn R.
A cell-permeable peptide inhibits activation of PKR and enhances cell proliferation.
Peptides. 21: 1449-56, 2000.
62)  Otsuka T, Jakubczak J, Vieira W, Bottaro DP, Breckenridge D, Larochelle WJ, Merlino G.
Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.
Mol. Cell. Biol. 20: 2055-65, 2000.
63)  Bies J, Feiková S, Bottaro DP, Wolff L.
Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases.
Oncogene. 19: 2846-54, 2000.
64)  Castagnino P, Lorenzi MV, Yeh J, Breckenridge D, Sakata H, Munz B, Werner S, Bottaro DP.
Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors.
Oncogene. 19: 640-8, 2000.
65)  Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, Cumberledge S, Rubin JS.
Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling.
J. Biol. Chem. 275: 4374-82, 2000.
66)  Day RM, Cioce V, Breckenridge D, Castagnino P, Bottaro DP.
Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis.
Oncogene. 18: 3399-406, 1999.
67)  LaRochelle WJ, Sakaguchi K, Atabey N, Cheon HG, Takagi Y, Kinaia T, Day RM, Miki T, Burgess WH, Bottaro DP.
Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor.
Biochemistry. 38: 1765-71, 1999.
68)  Zhou H, Casas-Finet JR, Heath Coats R, Kaufman JD, Stahl SJ, Wingfield PT, Rubin JS, Bottaro DP, Byrd RA.
Identification and dynamics of a heparin-binding site in hepatocyte growth factor.
Biochemistry. 38: 14793-802, 1999.
69)  Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, Aaronson SA.
Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling.
J. Biol. Chem. 274: 19465-72, 1999.
70)  Sakaguchi K, Lorenzi MV, Bottaro DP, Miki T.
The acidic domain and first immunoglobulin-like loop of fibroblast growth factor receptor 2 modulate downstream signaling through glycosaminoglycan modification.
Mol. Cell. Biol. 19: 6754-64, 1999.
71)  Otsuka T, Takayama H, Sharp R, Celli G, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M, Merlino G.
c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.
Cancer Res. 58: 5157-67, 1998.
72)  Kim PJ, Sakaguchi K, Sakamoto H, Saxinger C, Day R, McPhie P, Rubin JS, Bottaro DP.
Colocalization of heparin and receptor binding sites on keratinocyte growth factor.
Biochemistry. 37: 8853-62, 1998.
73)  Montesano R, Soriano JV, Malinda KM, Ponce ML, Bafico A, Kleinman HK, Bottaro DP, Aaronson SA.
Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis.
Cell Growth Differ. 9: 355-65, 1998.
74)  Castagnino P, Soriano JV, Montesano R, Bottaro DP.
Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor.
Oncogene. 17: 481-92, 1998.
75)  de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, Lechleider RJ.
Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases.
Genes Dev. 12: 1587-92, 1998.
76)  Zhou H, Mazzulla MJ, Kaufman JD, Stahl SJ, Wingfield PT, Rubin JS, Bottaro DP, Byrd RA.
The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site.
Structure. 6: 109-16, 1998.
77)  Shin DY, Ishibashi T, Choi TS, Chung E, Chung IY, Aaronson SA, Bottaro DP.
A novel human ERK phosphatase regulates H-ras and v-raf signal transduction.
Oncogene. 14: 2633-9, 1997.
78)  Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
EMBO J. 16: 5608-17, 1997.
79)  Stahl SJ, Wingfield PT, Kaufman JD, Pannell LK, Cioce V, Sakata H, Taylor WG, Rubin JS, Bottaro DP.
Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli.
Biochem. J. 326 ( Pt 3): 763-72, 1997.
80)  Li W, Zhang J, Bottaro DP, Pierce JH.
Identification of serine 643 of protein kinase C-delta as an important autophosphorylation site for its enzymatic activity.
J. Biol. Chem. 272: 24550-5, 1997.
81)  Cioce V, Csaky KG, Chan AM, Bottaro DP, Taylor WG, Jensen R, Aaronson SA, Rubin JS.
Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity.
J. Biol. Chem. 271: 13110-5, 1996.
82)  Li W, Chen XH, Kelley CA, Alimandi M, Zhang J, Chen Q, Bottaro DP, Pierce JH.
Identification of tyrosine 187 as a protein kinase C-delta phosphorylation site.
J. Biol. Chem. 271: 26404-9, 1996.
83)  Wadsworth P, Bottaro DP.
Microtubule dynamic turnover is suppressed during polarization and stimulated in hepatocyte growth factor scattered Madin-Darby canine kidney epithelial cells.
Cell Motil. Cytoskeleton. 35: 225-36, 1996.
84)  Nekhai S, Kumar A, Bottaro DP, Petryshyn R.
Peptides derived from the interferon-induced PKR prevent activation by HIV-1 TAR RNA.
Virology. 222: 193-200, 1996.
85)  Aroca P, Bottaro DP, Ishibashi T, Aaronson SA, Santos E.
Human dual specificity phosphatase VHR activates maturation promotion factor and triggers meiotic maturation in Xenopus oocytes.
J. Biol. Chem. 270: 14229-34, 1995.
86)  Rubin JS, Bottaro DP, Chedid M, Miki T, Ron D, Cheon G, Taylor WG, Fortney E, Sakata H, Finch PW.
Keratinocyte growth factor.
Cell Biol. Int. 19: 399-411, 1995.
87)  Rubin JS, Bottaro DP, Chedid M, Miki T, Ron D, Cunha GR, Finch PW.
Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction.
EXS. 74: 191-214, 1995.
88)  Ishibashi T, Bottaro DP, Michieli P, Kelley CA, Aaronson SA.
A novel dual specificity phosphatase induced by serum stimulation and heat shock.
J. Biol. Chem. 269: 29897-902, 1994.
89)  Adams DH, Harvath L, Bottaro DP, Interrante R, Catalano G, Tanaka Y, Strain A, Hubscher SG, Shaw S.
Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells.
Proc. Natl. Acad. Sci. U.S.A. 91: 7144-8, 1994.
90)  Cheon HG, LaRochelle WJ, Bottaro DP, Burgess WH, Aaronson SA.
High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains.
Proc. Natl. Acad. Sci. U.S.A. 91: 989-93, 1994.
91)  Bottaro DP, Fortney E, Rubin JS, Aaronson SA.
A keratinocyte growth factor receptor-derived peptide antagonist identifies part of the ligand binding site.
J. Biol. Chem. 268: 9180-3, 1993.
92)  Ron D, Bottaro DP, Finch PW, Morris D, Rubin JS, Aaronson SA.
Expression of biologically active recombinant keratinocyte growth factor. Structure/function analysis of amino-terminal truncation mutants.
J. Biol. Chem. 268: 2984-8, 1993.
93)  Rubin JS, Bottaro DP, Aaronson SA.
Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product.
Biochim. Biophys. Acta. 1155: 357-71, 1993.
94)  Chan A, Rubin J, Bottaro D, Hirschfield D, Chedid M, Aaronson SA.
Isoforms of human HGF and their biological activities.
EXS. 65: 67-79, 1993.
95)  Di Fiore PP, Helin K, Kraus MH, Pierce JH, Artrip J, Segatto O, Bottaro DP.
A single amino acid substitution is sufficient to modify the mitogenic properties of the epidermal growth factor receptor to resemble that of gp185erbB-2.
EMBO J. 11: 3927-33, 1992.
96)  Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA.
Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene.
Proc. Natl. Acad. Sci. U.S.A. 89: 246-50, 1992.
97)  Ishibashi T, Bottaro DP, Chan A, Miki T, Aaronson SA.
Expression cloning of a human dual-specificity phosphatase.
Proc. Natl. Acad. Sci. U.S.A. 89: 12170-4, 1992.
98)  Fazioli F, Bottaro DP, Minichiello L, Auricchio A, Wong WT, Segatto O, Di Fiore PP.
Identification and biochemical characterization of novel putative substrates for the epidermal growth factor receptor kinase.
J. Biol. Chem. 267: 5155-61, 1992.
99)  Molloy CJ, Fleming TP, Bottaro DP, Cuadrado A, Aaronson SA.
Platelet-derived growth factor stimulation of GTPase-activating protein tyrosine phosphorylation in control and c-H-ras-expressing NIH 3T3 cells correlates with p21ras activation.
Mol. Cell. Biol. 12: 3903-9, 1992.
100)  Chan AM, Rubin JS, Bottaro DP, Hirschfield DW, Chedid M, Aaronson SA.
Identification of a competitive HGF antagonist encoded by an alternative transcript.
Science. 254: 1382-5, 1991.
101)  Aaronson SA, Bottaro DP, Miki T, Ron D, Finch PW, Fleming TP, Ahn J, Taylor WG, Rubin JS.
Keratinocyte growth factor. A fibroblast growth factor family member with unusual target cell specificity.
Ann. N. Y. Acad. Sci. 638: 62-77, 1991.
102)  Segatto O, Lonardo F, Wexler D, Fazioli F, Pierce JH, Bottaro DP, White MF, Di Fiore PP.
The juxtamembrane regions of the epidermal growth factor receptor and gp185erbB-2 determine the specificity of signal transduction.
Mol. Cell. Biol. 11: 3191-202, 1991.
103)  Bottaro DP, Rubin JS, Ron D, Finch PW, Florio C, Aaronson SA.
Characterization of the receptor for keratinocyte growth factor. Evidence for multiple fibroblast growth factor receptors.
J. Biol. Chem. 265: 12767-70, 1990.
104)  Segatto O, Lonardo F, Pierce JH, Bottaro DP, Di Fiore PP.
The role of autophosphorylation in modulation of erbB-2 transforming function.
New Biol. 2: 187-95, 1990.
105)  Heidaran MA, Fleming TP, Bottaro DP, Bell GI, Di Fiore PP, Aaronson SA.
Transformation of NIH3T3 fibroblasts by an expression vector for the human epidermal growth factor precursor.
Oncogene. 5: 1265-70, 1990.
106)  Perlman R, Bottaro DP, White MF, Kahn CR.
Conformational changes in the alpha- and beta-subunits of the insulin receptor identified by anti-peptide antibodies.
J. Biol. Chem. 264: 8946-50, 1989.
107)  Bottaro DP, Bonner-Weir S, King GL.
Insulin receptor recycling in vascular endothelial cells. Regulation by insulin and phorbol ester.
J. Biol. Chem. 264: 5916-23, 1989.
108)  Molloy CJ, Bottaro DP, Fleming TP, Marshall MS, Gibbs JB, Aaronson SA.
PDGF induction of tyrosine phosphorylation of GTPase activating protein.
Nature. 342: 711-4, 1989.
109)  Ramponi G, Manao G, Camici G, Cappugi G, Ruggiero M, Bottaro DP.
The 18 kDa cytosolic acid phosphatase from bovine live has phosphotyrosine phosphatase activity on the autophosphorylated epidermal growth factor receptor.
FEBS Lett. 250: 469-73, 1989.
110)  Bottaro D, Shepro D, Hechtman HB.
Heterogeneity of intimal and microvessel endothelial cell barriers in vitro.
Microvasc. Res. 32: 389-98, 1986.
111)  Bottaro D, Shepro D, Peterson S, Hechtman HB.
Serotonin, norepinephrine, and histamine mediation of endothelial cell barrier function in vitro.
J. Cell. Physiol. 128: 189-94, 1986.
112)  Bottaro D, Shepro D, Peterson S, Hechtman HB.
Serotonin, histamine, and norepinephrine mediation of endothelial and vascular smooth muscle cell movement.
Am. J. Physiol. 248: C252-7, 1985.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/11/2014.